RE:RE:RE:Roche anti-TIGIT hope turns to TecentriqHere is another : " In March 2023, Merck & Co.'s TIGIT therapy tacked on to Keytruda did not improve progression-free survival in a phase 2 lung cancer trial, marking the another failure for the class."
Then in June 2023 Novartis ended its partnership with BeiGene on their TIGIT target.
https://www.fiercebiotech.com/biotech/merck-tacks-another-loss-anti-tigits-company-not-losing-hope-larger-strategy
https://medcitynews.com/2023/07/with-end-of-alliance-novartis-walks-away-from-once-hot-cancer-target/
https://www.gilead.com/news-and-press/press-room/press-releases/2022/12/anti-tigit-domvanalimab-containing-study-arms-improve-progression-free-survival-compared-to-anti-pd1-alone-in-phase-2-non-small-cell-lung-cancer-study